Merck + Co., Inc.

Merck Sharp + Dohme Corp.

Nicox S.a.

Robert K Baker

Kathleen M Rupprecht

William H Parsons

Jianming Bao

Frank Kayser

Shouwu Miao

Andrew Kotliar

Philippe L Durette

Amjad Ali

Arsenio A Pessolano

David A Claremon

Nigel J Liverton

Ravi P Nargund

Michael Man-Chu Lo

Christopher F Claiborne

Lin Yan

Wayne J Thompson

Hyun O Ok

Brent Whitehead

Shrenik K Shah

Bruce E Witzel

Dong-Ming Shen

Jeffrey John Hale

Peter J Sinclair

Ping Liu

Iyassu Sebhat

Ying-Duo Gao

Nicoletta Almirante

Linus S Lin

Harry R Chobanian

Linda L Chang

Yan Guo

Timothy J Henderson

Pei Huo

Maria L Garcia

Stefano Biondi

Gregory J Kaczorowski

Christopher L Franklin

Edward Metzger

Gerard R Kieczykowski

Zhiqiang Guo

Jun Wang

Marc D Chioda

Robert A Frankshun

James Dellureficio

Jennifer Chee

Massimiliano Ferrario

Alessia Nicotra

Chou Juitsai Liu

William A Schmalhofer

A compound having the structure: useful for treating hypertension, Pulmonary Arterial Hypertension (PAH), congestive heart failure, conditions resulting from excessive water retention, cardiovascular disease, diabetes, oxidative stress, endothelial dysfunction, cirrhosis, pre-eclampsia, osteoporosis or nephropathy. 

Diazeniumdiolate heterocyclic derivatives

A compound having the structure wherein Y is selected from the group consisting of &#x2014;C(O)OR, &#x2014;C(O)NHR, &#x2014;C(CH)OR3, OH, and or a pharmaceutically acceptable salt thereof, and methods of using the compounds for treating hypertension. 

Nitrooxy cycloalkane derivatives

Certain novel substituted diazepine sulfonamides are ligands of the human bombesin receptor and, in particular, are selective ligands of the human bombesin receptor subtype-3 (BRS-3). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of BRS-3, such as obesity, and diabetes. 

Substituted diazepine sulfonamides as bombesin receptor subtype-3 modulators

A compound having the structure wherein or a pharmaceutically acceptable salt thereof, and methods of using the compounds for treating hypertension.

Cicletanine derivatives

Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, Alzheimer's disease, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, cirrhosis of the liver, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH).

Heterocycle-substituted 3-alkyl azetidine derivatives

Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver. 

Substituted 3-alkyl and 3-alkenyl azetidine derivatives

The present invention relates to a class of carbocyclic compounds of Formula I that are useful as potassium channel inhibitors to treat autoimmune disorders, cardiac arrhythmias, and the like.

Carbocyclic potassium channel inhibitors

3-alkyl substituted pyrrolidine modulators of chemokine receptor activity

Pyrrolidine modulators of chemokine receptor activity

3-cyclopropyl and 3-cyclobutyl pyrrolidine modulators of chemokine receptor activity

This invention relates to benzamide potassium channel inhibitors of general structural Formula I.

Growing community of inventors

Cranford, NJ, United States of America

Robert K Baker